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cin does not cause adverse reactions compared with vehicle 
and is not absorbed through the intact or the inflamed va-
gina.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 The most common vaginal disorders include vaginal 
candidiasis, vaginal trichomoniasis and bacterial vagino-
sis  [1–5] . Forms of infectious vaginitis sustained by mixed 
micro-organisms are also observed frequently  [6] . Vagi-
nal infections can be successfully treated by using one or 
more pathogen-specific antimicrobials  [1, 3, 7–9] , but, be-
fore vaginitis is treated, the cause must be ascertained by 
using appropriate laboratory tests  [1, 2, 6, 7, 10] . Because 
some strains of  Candida albicans resistant to topical azole 
antifungals  [3, 11] and strains of  Trichomonas vaginalis 
 resistant to treatment with metronidazole and tinidazole 
 [12–14] have been recently isolated, it is also necessary to 
verify the susceptibility of micro-organisms to the rec-
ommended antimicrobials in certain cases  [3] . Therefore, 
many physicians find it difficult to diagnose accurately 
and manage these disorders in clinical practice  [15] . The 
availability of a drug effective in more than one form of 
infectious vaginitis would reduce the need for a confir-
matory diagnosis and the risk of treatment failure.
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 Abstract 
 Background/Aims: Intravaginal pentamycin is a polyene 
macrolide with a broad spectrum of antimicrobial activity 
and is effective in various forms of infectious vaginitis. We 
evaluated the safety, tolerability and pharmacokinetics of 
escalating doses of this product.  Methods: Nineteen healthy 
volunteers were randomized to receive double blind one of 
five doses of intravaginal pentamycin (3, 10, 30, 60 or 100 mg) 
or the corresponding dose of pentamycin vehicle daily for
6 days. Patients with symptomatic vaginitis received a single 
dose of 60 (n = 6) or 100 mg (n = 6) of intravaginal penta-
mycin. Safety and tolerability parameters were monitored 
throughout the study. Plasma concentrations of pentamycin 
were measured daily in the healthy volunteers and on the 
day of drug application in the patients.  Results: The most 
frequently reported adverse events were mild or moderate 
vaginal discharge and mild symptoms of vaginal irritation 
(mainly pruritus or burning sensation), which also occurred 
in women who applied the vehicle. No patient with symp-
tomatic vaginitis reported treatment-related adverse events. 
The plasma levels of pentamycin were below the quantifica-
tion limit in all samples.  Conclusion: Intravaginal pentamy-
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 Pentamycin is a polyene macrolide  [16, 17] with a 
broad spectrum of antimicrobial activity  [16, 18–20] . The 
3-mg dose strength of intravaginal pentamycin (Pruri-
ex  , 3-mg vaginal tablet) is registered in Switzerland for 
the treatment of various forms of infectious vaginitis 
(vaginal candidiasis, mixed infections and trichomonia-
sis). The currently approved treatment regimen is 3–6 mg 
daily for 5–10 days. A higher-dosed vaginal tablet of 
pentamycin (10-mg dose strength) may be effectively 
used for shorter treatment periods than the 3-mg dosage 
strength and is currently under clinical development. 
The purpose of this study was to evaluate the safety, tol-
erability and systemic absorption of escalating doses of 
intravaginal pentamycin in healthy female volunteers 
and in volunteers with symptomatic vaginitis.
 Patients and Methods 
 Ethics 
 The study was conducted in full compliance with the princi-
ples of the Declaration of Helsinki III and in accordance with the 
international guidelines of Good Clinical Practice. The study pro-
tocol was approved by an independent Ethics Committee (Ethi-
sche Kommission beider Basel, Basel, Switzerland). Written in-
formed consent to participate in the study was obtained from all 
subjects prior to study start.
 Part A of the Study 
 Part A was a double-blind, randomized, vehicle-controlled, 
escalating dose study in 19 female healthy volunteers (mean age: 
28.5 years; age range: 21–36 years). The inclusion and exclusion 
criteria are listed in  table 1 . The screening visit was performed 
between 24 h and 20 days before inclusion (day 1) and consisted 
of a medical history interview, collection of demographic charac-
teristics, physical examination, gynecological examination with 
colposcopy, measurement of pulse rate and blood pressure after 
3 min of rest in the supine position and after 1 min of standing, 
12-lead electrocardiogram (ECG), collection of blood and urine 
samples for laboratory tests, pregnancy test (for women in rep-
roductive age), and review of the inclusion and exclusion criteria. 
On day 1, the enrolled women were allocated to five dose groups 
as it follows:
 • Group 1: 3 mg of pentamycin or only vehicle (1 vaginal tablet) 
daily for 6 days; 
 • Group 2: 10 mg of pentamycin or only vehicle (1 vaginal tablet) 
daily for 6 days; 
 • Group 3: 30 mg of pentamycin or only vehicle (1 vaginal tablet) 
daily for 6 days 
 • Group 4: 60 mg of pentamycin or only vehicle (2 vaginal tab-
lets, containing each 30 mg of pentamycin or only vehicle, in 
single application) daily for 6 days 
 • Group 5: 100 mg of pentamycin or only vehicle (1 vaginal tab-
let) daily for 6 days. 
 Each dose was administered to 4 subjects. Within each group, 
subjects were assigned 3: 1 to treatment with the active compound 
or to the vehicle alone under blind conditions, according to a ran-
domization code. Subjects allocated to Groups 2–5 received treat-
ment only if women treated with the study drug in group 1 had 
not reported significant adverse events (AEs). One of the 19 en-
rolled women received more than one treatment (groups 1 and 4). 
This procedure was allowed by protocol and there were at least 2 
weeks of wash-out between completion of the first treatment and 
initiation of the second one. Drug application was avoided during 
menses. Male partners were instructed to use condoms during the 
treatment period and up to 48 h following the last application of 
the vaginal tablets.
 Subjects returned daily to the clinic for drug supply, recording 
of AEs and evaluation of the plasma concentrations of pentamy-
cin. Additional visits were conducted on day 3 (3rd day of treat-
ment), on day 7 (24 h after the last dose), and 8  8 2 days after the 
last treatment day (follow-up visit). A physical examination was 
performed at each of these visits. Pulse rate and blood pressure 
were recorded on the day of treatment start and on the last day of 
treatment. On both occasion, the pulse rate and blood pressure 
were measured after 3 min of rest in the supine position and after 
1 min of standing. The complete gynecological examination, 
ECG recording and laboratory assessment were repeated on day 
7. Blood sampling for the evaluation of pentamycin plasma con-
centrations was performed on day 1 before the first dose and then 
at 30 min, 1, 2, 4, 6, 12 and 24 h after the first dose. On days 2–5, 
blood sampling was performed only pre-dose. On day 6 (last ap-
plication), blood sampling was performed as on day 1. The last 
blood sampling was performed 24 h after the last dose (day 7).
 All vaginal tablets were prepared by an independent organiza-
tion (Fisher Clinical Services GmbH, Allschwil, Switzerland) and 
had similar aspect, shape and color. The randomization list was 
provided by the study sponsor (Lumavita AG, formerly Shogoo 
Pharmaceutical AG, Basel, Switzerland). The investigators re-
ceived code-breaking envelopes, containing the identity of the 
treatment dispensed to each subject. Breaking the code was al-
lowed only in case of a clinical emergency and upon receiving pri-
or approval from the sponsor. Any code break had to be justified 
in the case report form. At the end of the study, the unused code-
breaking envelopes were collected by the monitor for verification.
 Part B of the Study 
 Part B was an open-label study in 12 female volunteers (mean 
age: 32.7 years; age range: 19–59 years) with symptomatic vagini-
tis. The inclusion and exclusion criteria are listed in  table 1 . The 
screening visit was performed between 24 and 48 h before inclu-
sion and treatment (day 1). It consisted of a medical history inter-
view, collection of demographic characteristics, physical exami-
nation, gynecological examination with colposcopy, recording of 
pulse rate and blood pressure, collection of blood and urine sam-
ples for laboratory tests, pregnancy test (for women in reproduc-
tive age), and review of the inclusion and exclusion criteria. The 
cause of vaginitis was investigated by using saline wet mount and 
the potassium hydroxide test. On day 1, 6 women were asked to 
apply two vaginal tablets, each containing 30 mg of pentamycin 
(total dose: 60 mg in a single application). In absence of intoler-
ances, the remaining 6 women were asked to apply one vaginal 
tablet, containing 100 mg of pentamycin. Blood sampling for de-
termination of pentamycin plasma concentrations was performed 
pre-dose and then at 1, 3 and 8 h post-dose. The occurrence of AEs 
was registered during the entire post-dose period of observation. 
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Dosing was not performed during menses, and male partners 
were instructed to use condoms for 48 h following the application 
of the vaginal tablets.
 Assessment of AEs, Laboratory Parameters and
Plasma Levels of Pentamycin 
 All systemic and local AEs were recorded in the case report 
forms. For each AE, the investigator had to obtain adequate infor-
mation concerning the intensity, causal relationship with treat-
ment and outcome. AEs that met the criteria for classification as 
serious AEs were immediately reported to the sponsor.
 For the laboratory parameters, the normal range values were 
the standard reference values of the central laboratory of the Uni-
versity Hospital of Basel (Switzerland) where the analyses were 
performed. Plasma levels of pentamycin were measured by an in-
dependent laboratory (Swiss BioAnalytics AG, Birsfelden, Swit-
zerland) using high-performance liquid chromatography for sep-
aration of plasma proteins and mass spectrometry for  detection 
of pentamycin concentrations. The lower limit of quantification 
of the assay was 5 ng/ml.
 Results 
 Part A of the Study 
 All enrolled subjects completed part A of the study 
and were evaluated for safety and tolerability. No major 
differences in the occurrence of AEs could be detected 
across the dose groups and between the subjects treated 
with the active compound and those who received the 
vehicle ( table 2 ). There was no report of serious AEs, and 
all reported AEs were events of mild or moderate severity 
in most cases, with the sole exception of one case of severe 
abdominal pain in group 2 ( table 2 ), which was not con-
sidered to be related to study drug. Mild symptoms of 
vaginal irritation (mainly pruritus or burning sensation) 
were reported in women who applied 30 or 60 mg of 
pentamycin daily (group 3 and 4) and also in women who 
applied the vehicle alone (group 1 and 2;  table 2 ). The AEs 
Table 1.  Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Part A of the study
Age range: 18–45 years.
Body mass index: 19–25.
Use of a reliable contraception method.
Intact vaginal mucosa.
Healthy status, as determined by medical history, physical
examination, and 12-lead electrocardiogram at screening. 
Normal clinical laboratory tests at screening.
Negative tests for hepatitis B (surface antigen), hepatitis C and human 
immunodeficiency virus at screening.
Ability to understand the protocol and give informed consent.
Pregnant or lactating women.
History of genital problems that might interfere with the interpretation of 
results; acute gynecological symptoms at the time of screening or 
inclusion; significant abnormalities of the vaginal epithelium at the 
screening colposcopy.
Diseases involving other organs or systemic disorders; presence of an 
inflammatory process or an acute infection at screening or inclusion; 
abnormal liver or renal function.
Unwillingness to suspend the use of other vaginal products, such as douches, 
tampons, spermicides or herbal preparations during the study period.
History of relevant drug hypersensitivity.
Smoking; history of drug abuse or alcoholism, or consumption of more 
than 21 units of alcohol a week.
Use of prescription drugs or over-the-counter medications within 2 weeks 
of first dosing; use of investigational drugs within 1 month of first 
dosing.
Inability to communicate reliably with the investigator or to cooperate 
properly during the study.
Part B of the study
Age ≥18 years.
Symptoms of vaginitis, including itching, burning,
leukorrhea and xanthorrhea, and dyspareunia.
Confirmed diagnosis of bacterial vaginosis, candidiasis, or trichomoniasis.
Negative Papanicolaou smear documented less than 1 year
before screening.
Use of a reliable contraception method.
Ability to understand the protocol and give informed consent.
Pregnant or lactating women.
Abnormal liver or renal function; recent serious medical conditions that 
made the patients unsuitable for study participation.
Presence of a concomitant infection that needed an additional 
antimicrobial agent.
Unwillingness to suspend the use of other vaginal products, such as 
douches, tampons, spermicides or herbal preparations, during the 
study period.
History of relevant drug hypersensitivity.
Smoking; history of drug abuse or alcoholism, or consumption of more 
than 21 units of alcohol a week.
Use of investigational drugs within 1 month prior to screening. 
Inability to communicate reliably with the investigator or to cooperate 
properly during the study.
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listed as metrorrhagia according to the MedDRA Medi-
cal Dictionary ( table 2 ) were actually cases of intermedi-
ate bleeding that predominantly occurred in women with 
a history of irregular menses and intermediate bleeding 
and were not considered to be treatment related. In group 
3, one woman who received the active compound experi-
enced several AEs. Two of these events were not consid-
ered to be treatment-related (viral infection and vaginal 
burning sensation;  table  2 ). The other events included 
vaginal hemorrhage, vaginal discharge, vulvovaginal 
pruritus, and vaginal pain and were all considered as pos-
sibly or probably related to study drug ( table 2 ). About 4 
weeks after the last application of intravaginal pentamy-
cin, this subject experienced micturiation urgency and 
cystitis, which were also considered by the investigator as 
possibly related to study drug ( table 2 ). The woman was 
treated for 5 days with a combination of trimethoprine 
and sulfamethoxazole and symptoms resolved com-
pletely.
 All subjects who received the active treatment or the 
vehicle reported the appearance of mild or moderate vag-
inal discharge from the 2nd or 3rd day of study drug ap-
plication ( table 2 ). The discharge was usually white-grey 
and not disturbing, except for underwear staining. This 
AE was suspected to be due to an excipient of the vaginal 
tablet, and a sample of the discharge from women in 
group 5 was taken for analysis. Five batches of film-coat-
ed tablets, containing the active ingredient, and the resi-
dues of drug product after application (vaginal discharge) 
were compared by high-performance liquid chromatog-
raphy followed by mass spectrometry and ultraviolet de-
tection. This analysis excluded the presence of the active 
ingredient in the vaginal discharge.
 The gynecological examination performed within 
24 h  after  the last application of study drug confirmed 
the presence of vaginal discharge in most cases at the 
speculum exam but did not reveal alterations of the vag-
inal mucosa. Parts of incompletely dissolved vaginal tab-
lets were found in 7 women who had received the active 
treatment (one in group 2, one in group 3, 3 in group 4, 
and 2 in group 5). According to the investigator, this find-
ing is commonly observed with locally applied vaginal 
Table 2.  AEs, duration, and causality assessment for part A of the study
Group 1 Group 2 Group 3 Group 4 Group 5
AEs considered as not related or unlikely related to study drug
Active treatment (n = 3/group)
1 Metrorrhagia (T) 1 Abdominal pain (1 day)
1 Aphthous stomatitis
(1 day)
1 Metrorrhagia (T)
1 Diarrhea (T)
1 Malaise (4 days) 
1 Viral infection (1 day)
1 Vaginal burning sensation (3 days)
1 Vulvovaginal pruritus (T) 
1 Flatulence (T)
1 Laryngitis (5 days)
1 Nasopharyngitis (4 days) 
1 Dizziness (T)
1 Headache (T)
1 Perianal erythema/
eczema (13 days)
1 Pityriasis (23 days)
Vehicle (n = 1/group)
Tendinitis (2 days) Headache (3 days) 
Malaise (3 days) 
Nausea (1 day)
Back pain (1 day)
Conjunctival irritation (2 days)
Pelvic pain (1 day)
AEs considered as possibly or probably related to study drug
Active treatment (n = 3/group)
3 Vaginal discharge (T-2 days)
1 Vulvar erythema (T)
3 Vaginal discharge
(T-4 days)
3 Vaginal discharge (1–4 days)
2 Abdominal pain (1–5 days)
1 Abdominal discomfort (7 days)
1 Cystitis (4 days)1
1 Micturition urgency (4 days)1
1 Vaginal hemorrhage (4 days)
1 Vaginal pain (unchanged at follow-up)
1 Vulvar edema (NR)
1 Vulvovaginal pruritus (T)
3 Vaginal discharge (5–13 days)
1 Vaginal burning sensation
(2 days)
1 Vaginal pain (1 day)
1 Vulvovaginal pruritus (7 days)
3 Vaginal discharge
(5–6 days)
Vehicle (n = 1/group)
Vaginal burning sensation (1 day)
Vaginal discharge (4 days)
Vaginal discharge (3 days)
Vulvovaginal pruritus
(2 days)
Abdominal pain (2 days)
Vaginal discharge (3 days)
Pelvic pain (T)
Vaginal discharge (11 days)
Vaginal discharge
(3 days)
T = Transient AE, resolving on the day of its occurrence; NR = not recorded.
1 This AE occurred 26 days after treatment end. 
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tablets. Persistent vaginal discharge was reported at the 
follow-up visit by 5 women: 4 had received the active 
treatment (one in group 1, one in group 3 and 2 in group 
5) and one had received the vehicle (group 5). One case of 
vaginal pain in a woman who received the active treat-
ment in group 3 ( table 2 ) was also reported as unchanged 
at the follow-up visit. This AE started 2 days before the 
end of the treatment period. Two women who received 
the active treatment in group 5 experienced perianal ery-
thema/eczema and pytiriasis versicolor, respectively, dur-
ing the study period ( table 2 ). None of these AEs were 
considered to be related to study drug and were treated 
with specific topical agents. The other AEs resolved spon-
taneously by the end of the study.
 There were no substantial changes in blood pressure 
from the time of treatment start to the end of the treat-
ment period across the dose groups and between the sub-
jects treated with the active compound and those who 
received the vehicle ( table 3 ). On ECG recordings, sinus 
bradycardia (sinus rate  ! 60 beats/min) was noted in 5 
cases at the screening visit and was confirmed at the end 
of the treatment period only in one case. This woman was 
the one who reported a mild and short-lasting episode of 
dizziness during the application of the active compound 
in group 5 ( table 2 ) and such event was not considered as 
treatment-related. In another woman, bradycardia was 
not present at the screening visit but was detected on day 
7. This subject had received the vehicle. The laboratory 
parameters did not show significant changes attributable 
to the type of treatment received or to the dose of active 
ingredient applied during the treatment period. The plas-
ma levels of pentamycin were below the limit of quantifi-
cation in all samples.
 Part B of the Study 
 All enrolled women reported symptoms of vaginitis, 
including itching, burning, leukorrhea and xanthorrhea, 
and dyspareunia, as required by the protocol. The cause 
of vaginitis was investigated by using saline wet mount 
and the potassium hydroxide test. Four women were di-
agnosed with bacterial vaginosis and 8 with mixed infec-
tions (bacterial vaginosis and candidiasis). No case of 
trichomoniasis was identified. In 6 cases, the vaginal dis-
charge specimen was sent to the local Institute of Micro-
biology, although microbiology testing was not required 
by protocol. The isolation of  C. albicans and/or  Gardne-
rella vaginalis  confirmed the diagnosis of candidiasis, 
mixed infections or bacterial vaginosis in these women.
 Five of 6 patients in the 60-mg dose group reported 
the following AEs: vaginal burning sensation (2 women), 
vaginal discharge (2 women), pruritus (one woman), 
vaginal pain (one woman) and cystitis (one woman). 
Only one of the patients who received the highest dose of 
pentamycin reported an AE (cystitis). All events were 
mild or moderate in severity and were considered as not 
related or unlikely related to study drug. Except for one 
case of vaginal discharge (60-mg dose group) and one 
case of cystitis (100-mg dose group) the events resolved 
promptly after appropriate treatment (started 8 h follow-
ing the application of study drug). The plasma levels of 
pentamycin were below the limit of quantification in all 
samples.
 Discussion 
 Pentamycin exhibits a broad spectrum of antimicro-
bial activity in vitro and in vivo  [16, 18–20] . In particular, 
its in vitro activity against various  Candida species is 
similar to that of the azole antifungal agent miconazole 
and its activity against trichomonads is similar to that of 
metronidazole. Pentamycin is also active against several 
pathogenic bacterial strains, including  G. vaginalis and 
other strains involved in bacterial vaginoses and mixed 
infections, but it is inactive against the lactobacilli that 
colonize the normal vagina  [19] . Because of the high mo-
lecular weight (molar mass = 670.85 g/mol) and bipolar 
molecular structure  [21] , topically applied pentamycin 
has a low potential of penetrating through the intact mu-
cosa into the circulation. Compared to other antimicro-
bials recommended for the treatment of vaginal infec-
Table 3.  Blood pressure recording for part A of the study
Treatment Mean blood pressure on
day 1, mm Hg
Mean blood pressure on
day 7, mm Hg
supine standing supine s tanding
SBP DBP SBP DBP SBP DBP SBP DBP
Active treatment 
Group 1 111 70 116 69 110 69 104 75
Group 2 106 70 109 73 117 76 101 67
Group 3 112 70 111 77 110 67 103 76
Group 4 112 68 116 76 110 67 109 71
Group 5 115 71 118 79 106 68 113 79
 Vehicle 107 67 120 72 108 68 114 72
SB P = Systolic blood pressure; DBP = diastolic blood pressure. 
Active treatment: n = 3/group; vehicle: n = 5, 1/group.
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tions  [1, 3] , which are pathogen-specific and require labo-
ratory tests to ascertain the nature of the causative agent, 
intravaginal pentamycin offers the advantage of being ef-
fective in more than one form of vaginitis  [20, 22] . Be-
cause of a broader spectrum of antimicrobial activity, it 
is also superior to other potential therapeutic options  [23] 
or drug candidates  [24] . The favorable tolerability profile 
of this drug is supported by the absence of reports of ad-
verse reactions in the population of over 40,000 patients 
who have been treated with intravaginal pentamycin in 
clinical practice since the first registration in Switzerland 
of the 3-mg dose strength (data on file at Lumavita AG, 
Basel, Switzerland).
 As part of the clinical development program for a 
higher-dosed vaginal tablet of pentamycin (10-mg dose 
strength), this study evaluated the safety, tolerability and 
systemic absorption of escalating doses of intravaginal 
pentamycin. We found that the administration of in-
creasing doses of intravaginal pentamycin up to a maxi-
mal dose of 100 mg daily for 6 days in healthy women did 
not result in a dose-dependent increase in the risk of sys-
temic or local AEs as compared to the vehicle alone. Most 
reported AEs were of mild or moderate intensity. There 
was no serious AE and no discontinuation due to AEs. 
Irrespective of the dose group and treatment received (ei-
ther the active compound or the vehicle), all women re-
ported the appearance of a white-grey vaginal discharge 
from the 2nd or 3rd day of study drug application. The 
vaginal discharge did not contain the active ingredient 
and was probably due to an excipient of the vaginal tab-
lets. The gynecological examination performed after 
treatment completion did not reveal any abnormality of 
the vaginal mucosa. In a woman who received the active 
treatment, cystitis was diagnosed approximately 4 weeks 
after the last dosing. The time elapsed between treatment 
completion and the occurrence of symptoms of cystitis 
would suggest a doubtful causal relationship between the 
event and the application of intravaginal pentamycin. 
Moreover, the subject had reported a viral infection not 
considered as treatment-related during the treatment pe-
riod and this AE may have represented a confounding 
factor. Blood pressure, ECG parameters and laboratory 
parameters did not change significantly in relation to the 
treatment received during the study period or in relation 
to the dose of the active compound. The intravaginal ap-
plication of pentamycin did not result in a detectable sys-
temic absorption of the active compound into the circula-
tion because the plasma levels of pentamycin were invari-
ably below the detection limit of 5 ng/ml, irrespective of 
the dose of pentamycin administered. The total observa-
tion period was 120 treatment days (90 for the active com-
pound and 30 for the placebo) and the highest dose ap-
plied was 10 ! the assumed therapeutic dose of 10 mg 
daily that should be given for 3 days.
 The AEs reported by patients with symptomatic vagi-
nitis who applied a single dose of either 60 or 100 mg of 
intravaginal pentamycin in the part B of this study were 
all mild or moderate local events. These AEs were not 
considered to be treatment related and were probably due 
to the underlying disease. Notably, the administration of 
a dose of intravaginal pentamycin that is 10 ! the as-
sumed therapeutic dose of 10 mg daily in these patients 
with inflamed vagina was not associated with the pres-
ence of detectable levels of the active ingredients in the 
circulation.
 In conclusion, our study demonstrates that the intra-
vaginal administration of pentamycin at a dose as high as 
100 mg daily for up to 6 days does not cause an increase 
in the occurrence of local or systemic adverse reactions 
in comparison with the vehicle alone and is not associ-
ated with systemic absorption of the active ingredient 
through the intact or the inflamed vagina.
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